188 results on '"Bagley, Rebecca G."'
Search Results
2. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer
3. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
4. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
5. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
6. Supplementary Figure Legends and Supplementary Tables 1 and 2 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
7. Supplementary Figure 1 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
8. Supplementary Figure 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
9. Supplementary Figure 3 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
10. Supplementary Figure 2 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
11. Supplementary Table 1 from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
12. Supplementary Figure 4 from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
13. Data from Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
14. Data from sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
15. Adrenomedullin
16. Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
17. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
18. Endothelial Precursor Cells
19. Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)
20. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells
21. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
22. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
23. Additional file 1 of A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
24. Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer
25. Endosialin: from vascular target to biomarker for human sarcomas
26. Framework multipoint map of the long arm of human Chromosome 4 and telomeric localization of the gene for FSHD
27. The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1Mutant AML: Updated Results of a Phase (Ph) 1 Study
28. Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr)and mNPM1 (NPM1c)leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
29. A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
30. A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.
31. Prevalence and clinical implications of T-cell immunoglobulin mucin type-1 (TIM-1) in multiple tumor types.
32. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2ArAcute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study
33. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2ArAcute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study
34. Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma
35. Abstract 1373: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues
36. Commentary on Folkman: “Tumor Angiogenesis Factor”
37. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice
38. Endothelial Precursor Cells
39. Abstract 4809: Enhanced activity of aflibercept compared to bevacizumab in a patient-derived xenograft colorectal cancer model is associated with reduced tumor vascularity in humanized VEGF mice
40. Abstract 4808: Aflibercept is highly active in clinically relevant, patient derived xenografts of colorectal cancer
41. Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
42. Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.
43. Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia
44. Tumor endothelial marker 7 (TEM-7): A novel target for antiangiogenic therapy
45. Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment
46. Abstract 1596: Human choriocarcinomas: Placental growth factor-dependent preclinical tumor models
47. Characteristics of Human Ewing/PNET Sarcoma Models
48. Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
49. sFLT01: A Novel Fusion Protein with Antiangiogenic Activity
50. Abstract 1388: sFLT01: An anti-angiogenic fusion protein that neutralizes placental growth factor (PlGF) and vascular endothelial growth factor (VEGF)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.